Modus Therapeutics Holding AB AI Stock Analysis
Want to see SE:MODTX full AI Analyst Report?
Modus Therapeutics Holding AB (MODTX) AI Stock Analysis
Modus Therapeutics Holding AB
(Nasdaq OMX AB:MODTX)
The score is held down primarily by weak financial performance (pre-revenue, sustained losses and high cash burn implying ongoing funding needs) and very bearish technicals (price far below major moving averages with negative MACD). A debt-free balance sheet and improved equity provide some near-term financial flexibility, but valuation remains difficult to support due to negative earnings and no dividend data.
Modus Therapeutics Holding AB (MODTX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 25.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.24M
- Price to Earnings (P/E)
- -0.8
- Beta (1Y)
- 2.10
- Revenue Growth
- ―
- EPS Growth
- 0.22%
- Country
- Sweden
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Modus Therapeutics Holding AB Business Overview & Revenue Model
Company Description
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated w...
How the Company Makes Money
Modus Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it does not appear to generate recurring commercial product revenue. Its business model is primarily to fund and advance its drug development p...
Modus Therapeutics Holding AB Financial Statement Overview
Summary
Overall financial health is weak: the company is pre-revenue with persistent, significant operating and net losses (TTM EBIT about -17.5M; net loss about -17.6M) and materially negative operating/free cash flow (TTM about -18.6M). The main offset is a currently conservative balance sheet with zero debt and improved equity (TTM equity about 10.2M), but returns on equity remain strongly negative and the model depends on continued external funding.
Income Statement
12Very NegativeBalance Sheet
48NeutralCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -17.47M | -18.17M | -15.84M | 2,000 | 0 | -20.69M |
| Net Income | -17.59M | -18.54M | -15.54M | -17.90M | -18.32M | -20.69M |
Balance Sheet | ||||||
| Total Assets | 13.28M | 12.69M | 4.88M | 20.04M | 11.27M | 21.19M |
| Cash, Cash Equivalents and Short-Term Investments | 12.49M | 11.37M | 4.38M | 19.06M | 10.42M | 20.65M |
| Total Debt | 0 | 0 | 0 | 0 | 11.50M | 0 |
| Total Liabilities | 3.04M | 3.62M | 2.75M | 2.36M | 13.86M | 5.46M |
| Stockholders Equity | 10.24M | 9.07M | 2.14M | 17.68M | -2.58M | 15.73M |
Cash Flow | ||||||
| Free Cash Flow | -18.57M | -18.07M | -14.68M | -16.68M | -21.72M | -16.08M |
| Operating Cash Flow | -18.57M | -18.07M | -14.68M | -16.68M | -21.72M | -16.08M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | -50.00K |
| Financing Cash Flow | 29.16M | 25.07M | 0 | 25.32M | 11.50M | 29.43M |
Modus Therapeutics Holding AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MODTX, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.17, below the 50-day MA of 0.28, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 27.26 is Positive, neither overbought nor oversold. The STOCH value of 14.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MODTX.
Modus Therapeutics Holding AB Peers Comparison
Overall Rating
SE:CANTA74Outperform
SE:HNSA60Neutral
SE:BINV49Neutral
SE:IMMU48Neutral
SE:VICO44Neutral
SE:MODTX41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 74Outperform | SEK 360.61M | 1.88 | 63.09% | ― | ― | ― | |
| 60Neutral | SEK 4.87B | -6.06 | ― | ― | 68.88% | 10.63% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 172.08M | -0.35 | -128.54% | ― | -83.67% | -50.29% | |
| 48Neutral | SEK 228.36M | -2.01 | -19.14% | ― | ― | 13.06% | |
| 44Neutral | SEK 2.90B | -5.47 | -55.97% | ― | -54.97% | -1.66% | |
| 41Neutral | SEK 25.61M | -0.83 | -177.45% | ― | ― | 0.22% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:MODTX | Modus Therapeutics Holding AB | 0.15 | -0.25 | -62.53% | |
| SE:HNSA | Hansa Biopharma | 47.88 | 20.06 | 72.11% | |
| SE:BINV | BioInvent International AB | 2.62 | -28.28 | -91.54% | |
| SE:VICO | Vicore Pharma Holding AB | 10.28 | -0.06 | -0.58% | |
| SE:IMMU | Immunicum AB | 3.60 | -2.00 | -35.71% | |
| SE:CANTA | Cantargia AB | 1.28 | -1.95 | -60.40% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026
